Tiofarma Admits Involvement On UK Fludrocortisone
UK’s CMA Announces Agreement To Pay Up To £186,000
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.
You may also be interested in...
The UK’s CMA has accused Tiofarma and Amilco of colluding with Aspen over an illegal agreement that resulted in significant price hikes for fludrocortisone.
Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.